User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

Primary tabs

van Vollenhoven, Ronald F Mosca, Marta Bertsias, George Isenberg, David Kuhn, Annegret Houssiau, Frédéric [UCL] Schneider, Matthias

The principle of treating-to-target has been successfully applied to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and pursuing these systematically has led to improved care for patients with these diseases and useful guidance for healthcare providers and administrators. Thus, an initiative to evaluate possible therapeutic targets and develop treat-to-target guidance was believed to be highly appropriate in the management of systemic lupus erythematosus (SLE) patients as well. Specialists in rheumatology, nephrology, dermatology, internal medicine and clinical immunology, and a patient representative, contributed to this initiative. The majority convened on three occasions in 2012-2013. Twelve topics of critical importance were identified and a systematic literature review was performed. The results were condensed and reformulated as recommendations, discussed, modified and voted upon. The finalised bullet points were analysed for degree of agreement among the task force. The Oxford Centre level of evidence (LoE, corresponding to the research questions) and grade of recommendation (GoR) were determined for each recommendation. The 12 systematic literature searches and their summaries led to 11 recommendations. Prominent features of these recommendations are targeting remission, preventing damage and improving quality of life. LoE and GoR of the recommendations were variable but agreement was >0.9 in each case. An extensive research agenda was identified, and four overarching principles were also agreed upon. Treat-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative. It is anticipated that 'treating-to-target' can and will be applicable to the care of patients with SLE.

Document type Article de périodique (Journal article)
Publication date 2014
Language Anglais
Journal information "Annals of the rheumatic diseases" - Vol. 73, no.6, p. 958-67 (2014)
Peer reviewed yes
issn 1468-2060
Publication status Publié
Affiliations UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales
UCL - (SLuc) Service de rhumatologie
Links
  1. Terrier Benjamin, Amoura Zahir, Ravaud Philippe, Hachulla Eric, Jouenne Romain, Combe Bernard, Bonnet Christine, Cacoub Patrice, Cantagrel Alain, De Bandt Michel, Fain Olivier, Fautrel Bruno, Gaudin Philippe, Godeau Bertrand, Harlé Jean-Robert, Hot Arnaud, Kahn Jean-Emmanuel, Lambotte Olivier, Larroche Claire, Léone Jean, Meyer Olivier, Pallot-Prades Béatrice, Pertuiset Edouard, Quartier Pierre, Schaerverbeke Thierry, Sibilia Jean, Somogyi Alexandre, Soubrier Martin, Vignon Eric, Bader-Meunier Brigitte, Mariette Xavier, Gottenberg Jacques-Eric, Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry, 10.1002/art.27541
  2. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson E W, Klareskog L, van Vollenhoven R F, Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response, 10.1136/ard.2007.079095
  3. Petri M. A., Kiani A. N., Post W., Christopher-Stine L., Magder L. S., Lupus Atherosclerosis Prevention Study (LAPS), 10.1136/ard.2010.136762
  4. Norby Gudrun E., Holme Ingar, Fellström Bengt, Jardine Alan, Cole Edward, Abedini Sadollah, Holdaas Hallvard, , Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placebo-controlled study, 10.1002/art.24379
  5. Burgos PI, Vilá LM, Reveille JD, Alarcón GS, Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX), 10.1177/0961203309105877
  6. McLaurin E. Y., Holliday S. L., Williams P., Brey R. L., Predictors of cognitive dysfunction in patients with systemic lupus erythematosus, 10.1212/01.wnl.0000149640.78684.ea
  7. Duran-Barragan S., McGwin G., Vila L. M., Reveille J. D., Alarcon G. S., Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort, 10.1093/rheumatology/ken208
  8. Zheng ZH, Zhang LJ, Liu WX, Lei YS, Xing GL, Zhang JJ, Quan SX, Liu D, Hu DS, Li LL, Liu ZS, Predictors of survival in Chinese patients with lupus nephritis, 10.1177/0961203312445230
  9. Urowitz Murray B., Gladman Dafna D., Tom Brian D.M., Ibañez Dominique, Farewell Vernon T., Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus, 10.3899/jrheum.080214
  10. Ruiz-Irastorza G, Egurbide M-V, Pijoan J-I, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain J-G, Aguirre C, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus, 10.1177/0961203306071872
  11. Ibanez, J Rheumatol, 32, 824 (2005)
  12. Fessler Barri J., Alarcón Graciela S., McGwin Gerald, Roseman Jeffrey, Bastian Holly M., Friedman Alan W., Baethge Bruce A., Vilá Luis, Reveille John D., , Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, 10.1002/art.21039
  13. Cavazzana I, Sala R, Bazzani C, Ceribelli A, Zane C, Cattaneo R, Tincani A, Calzavara-Pinton PG, Franceschini F, Treatment of lupus skin involvement with quinacrine and hydroxychloroquine, 10.1177/0961203308101714
  14. Bezerra Elaine Lira Medeiros, Vilar Maria José Pereira, da Trindade Neto Pedro Bezerra, Inoue Sato Emı´lia, Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus, 10.1002/art.21358
  15. , Tsakonas E, Joseph L, Esdaile J M, Choquette D, Senécal J-L, Cividino A, Danoff D, Osterland C K, Yeadon C, Smith C D, A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus, 10.1191/096120398678919778
  16. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M A, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, 10.1136/ard.2008.101766
  17. Tan BE, Thong BYH, Shivananda S, Han WW, Chng HH, Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort, 10.1177/0961203309103303
  18. Khamashta Munther A., Cuadrado Maria Jose, Mujic Fedza, Taub Nick A., Hunt Beverley J., Hughes Graham R.V., The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome, 10.1056/nejm199504133321504
  19. FINAZZI G., MARCHIOLI R., BRANCACCIO V., SCHINCO P., WISLOFF F., MUSIAL J., BAUDO F., BERRETTINI M., Testa S., D'ANGELO A., TOGNONI G., BARBUI T., A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1, 10.1111/j.1538-7836.2005.01340.x
  20. Crowther Mark A., Ginsberg Jeff S., Julian Jim, Denburg Judah, Hirsh Jack, Douketis James, Laskin Carl, Fortin Paul, Anderson David, Kearon Clive, Clarke Ann, Geerts William, Forgie Melissa, Green David, Costantini Lorrie, Yacura Wendy, Wilson Sarah, Gent Michael, Kovacs Michael J., A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome, 10.1056/nejmoa035241
  21. Tektonidou Maria G., Laskari Katerina, Panagiotakos Demosthenes B., Moutsopoulos Haralampos M., Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, 10.1002/art.24232
  22. Ruiz-Irastorza Guillermo, Crowther Mark, Branch Ware, Khamashta Munther A, Antiphospholipid syndrome, 10.1016/s0140-6736(10)60709-x
  23. Tarr T, Lakos G, Bhattoa H P, Shoenfeld Y, Szegedi G, Kiss E, Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients, 10.1177/0961203306074767
  24. Mok, J Rheumatol, 32, 622 (2005)
  25. Ruiz-Irastorza G, Egurbide M-V, Martinez-Berriotxoa A, Ugalde J, Aguirre C, Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus, 10.1191/0961203304lu2030oa
  26. MAZZANTINI M., TALARICO R., DOVERI M., CONSENSI A., CAZZATO M., BAZZICHI L., BOMBARDIERI S., Incident Comorbidity Among Patients with Rheumatoid Arthritis Treated or Not with Low-dose Glucocorticoids: A Retrospective Study, 10.3899/jrheum.100461
  27. MAZZANTINI M., TORRE C., MICCOLI M., BAGGIANI A., TALARICO R., BOMBARDIERI S., DI MUNNO O., Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study, 10.3899/jrheum.110851
  28. Rygg Marite, Pistorio Angela, Ravelli Angelo, Maghnie Mohamad, Di Iorgi Natascia, Bader-Meunier Brigitte, Da Silva Carlos, Roldan-Molina Rosa, Barash Judith, Dracou Cristina, Laloum Sylvie Gandon, Jarosova Katerina, Deslandre Chantal Job, Koné-Paut Isabelle, Garofalo Franco, Press Joseph, Sengler Claudia, Tauber Tsivia, Martini Alberto, Ruperto Nicolino, A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus, 10.1136/annrheumdis-2011-200106
  29. THAMER M., HERNAN M. A., ZHANG Y., COTTER D., PETRI M., Prednisone, Lupus Activity, and Permanent Organ Damage, 10.3899/jrheum.080828
  30. Yap, Rheumatology (Oxford)
  31. LASKARI K., TZIOUFAS A. G., ANTONIOU A., MOUTSOPOULOS H. M., Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis, 10.3899/jrheum.101249
  32. Houssiau F A, Vasconcelos C, D'Cruz D, Sebastiani G D, de Ramon Garrido E, Danieli M G, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico R A, Cattaneo R, Font J, Depresseux G, Cosyns J-P, Cervera R, The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide, 10.1136/ard.2008.102533
  33. Mok Chi Chiu, Ying King Yee, Ng Woon Leung, Lee Ka Wing, To Chi Hung, Lau Chak Sing, Wong Raymond Woon Sing, Au Tak Cheung, Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide, 10.1016/j.amjmed.2005.08.045
  34. Ginzler Ellen, Sharon Ezra, Diamond Herbert, Kaplan David, Long-term maintenance therapy with azathioprine in systemic lupus erythematosus, 10.1002/art.1780180106
  35. Boumpas D.T., Austin H.A., Balow J.E., Vaughan E.M., Yarboro C.H., Klippel J.H., Steinberg A.D., Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis, 10.1016/0140-6736(92)92292-n
  36. Henderson, Cochrane Database Syst Rev, 12, CD002922 (2012)
  37. Fernandes Moca Trevisani, Cochrane Database Syst Rev, 2, CD002265 (2013)
  38. Lu X, Gu Y, Wang Y, Chen S, Ye S, Prognostic factors of lupus myelopathy, 10.1177/0961203307088005
  39. Harisdangku Valee, Doorenbos David, Subramony S. H., Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment, 10.1007/bf00878876
  40. Rzany B, Coresh J, Whelton P K, Petri M, Risk factors for hypercreatinemia in patients with systemic lupus erythematosus, 10.1191/096120399678840828
  41. Jacobsen, Henrik Starklint, Jørgen Søren, Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine, 10.1080/03009749950155472
  42. Ioannidis John P.A., Boki Kyriaki A., Katsorida Maria E., Drosos Alexandros A., Skopouli Fotini N., Boletis John N., Moutsopoulos Haralampos M., Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide, 10.1046/j.1523-1755.2000.00832.x
  43. Esdaile, Q J Med, 72, 779 (1989)
  44. Dall'era, Arthritis Care Res, 63, 351 (2011)
  45. Faurschou Mikkel, Dreyer Lene, Kamper Anne-Lise, Starklint Henrik, Jacobsen Søren, Long-term mortality and renal outcome in a cohort of 100 patients with Lupus Nephritis, 10.1002/acr.20116
  46. So Min Wook, Koo Bon San, Kim Yong-Gil, Lee Chang-Keun, Yoo Bin, Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis, 10.1007/s10067-011-1778-2
  47. van Vollenhoven Ronald F, Petri Michelle A, Cervera Ricard, Roth David A, Ji Beulah N, Kleoudis Christi S, Zhong Z John, Freimuth William, Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response, 10.1136/annrheumdis-2011-200937
  48. Strand V, Aranow C, Cardiel M H, Alarcon-Segovia D, Furie R, Sherrer Y, Tumlin J, Wallace D J, Crawford B, , Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo, 10.1191/0961203303lu440oa
  49. Grootscholten, J Rheumatol, 34, 1699 (2007)
  50. Moorthy LN, Peterson MGE, Hassett AL, Baratelli M, Chalom EC, Hashkes PJ, Hong S, Reiff A, Lehman TJA, Relationship between health-related quality of life and SLE activity and damage in children over time, 10.1177/0961203308101718
  51. Mok C. C., Ho L. Y., Cheung M. Y., Yu K. L., To C. H., Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2‐year prospective study, 10.1080/03009740802415527
  52. Kuriya Bindee, Gladman Dafna D., Ibañez Dominque, Urowitz Murray B., Quality of life over time in patients with systemic lupus erythematosus, 10.1002/art.23339
  53. APPENZELLER S., CLARKE A. E., PANOPALIS P., JOSEPH L., ST. PIERRE Y., LI T., The Relationship Between Renal Activity and Quality of Life in Systemic Lupus Erythematosus, 10.3899/jrheum.080822
  54. Yazdany Jinoos, Trupin Laura, Gansky Stuart A., Dall'Era Maria, Yelin Edward H., Criswell Lindsey A., Katz Patricia P., Brief index of lupus damage: A patient-reported measure of damage in systemic lupus erythematosus, 10.1002/acr.20503
  55. Doria A., Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants, 10.1093/rheumatology/keh392
  56. AGGARWAL R., WILKE C. T., PICKARD A. S., VATS V., MIKOLAITIS R., FOGG L., BLOCK J. A., JOLLY M., Psychometric Properties of the EuroQol-5D and Short Form-6D in Patients with Systemic Lupus Erythematosus, 10.3899/jrheum.081022
  57. ZHU T. Y., TAM L.-S., LEE V. W.Y., LEE K. K., LI E. K., Relationship Between Flare and Health-related Quality of Life in Patients with Systemic Lupus Erythematosus, 10.3899/jrheum.090876
  58. McELHONE K., CASTELINO M., ABBOTT J., BRUCE I. N., AHMAD Y., SHELMERDINE J., PEERS K., ISENBERG D., FERENKEH-KOROMA A., GRIFFITHS B., AKIL M., MADDISON P., GORDON C., TEH L.-S., The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus, 10.3899/jrheum.091277
  59. Jolly M, Pickard A S, Wilke C, Mikolaitis R A, Teh L-S, McElhone K, Fogg L, Block J, Lupus-specific health outcome measure for US patients: the LupusQoL-US version, 10.1136/ard.2008.094763
  60. Kiani Adnan N., Petri Michelle, Quality-of-Life Measurements Versus Disease Activity in Systemic Lupus Erythematosus, 10.1007/s11926-010-0114-1
  61. Dua Anisha B., Touma Zahi, Toloza Sergio, Jolly Meenakshi, Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus, 10.1007/s11926-013-0380-9
  62. Ramsey-Goldman R, Alarcón GS, McGwin G, Petri M, Vilá LM, Edberg JC, Reveille JD, Kimberly RP, Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort, 10.1177/0961203307086639
  63. Mak Anselm, Cheung Mike W.-L., Chiew Hui Jin, Liu Yang, Ho Roger Chun-man, Global Trend of Survival and Damage of Systemic Lupus Erythematosus: Meta-Analysis and Meta-Regression of Observational Studies from the 1950s to 2000s, 10.1016/j.semarthrit.2011.11.002
  64. Hanly John G, Urowitz Murray B, Su Li, Gordon Caroline, Bae Sang-Cheol, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Wallace Daniel J, Clarke Ann E, Ginzler EM, Merrill Joan T, Isenberg David A, Rahman Anisur, Petri M, Fortin Paul R, Gladman DD, Bruce Ian N, Steinsson Kristjan, Dooley MA, Khamashta Munther A, Alarcón Graciela S, Fessler Barri J, Ramsey-Goldman Rosalind, Manzi Susan, Zoma Asad A, Sturfelt Gunnar K, Nived Ola, Aranow Cynthia, Mackay Meggan, Ramos-Casals Manuel, van Vollenhoven RF, Kalunian Kenneth C, Ruiz-Irastorza Guillermo, Lim Sam, Kamen Diane L, Peschken Christine A, Inanc Murat, Theriault Chris, Thompson Kara, Farewell Vernon, Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study, 10.1136/annrheumdis-2011-201089
  65. Chambers S. A., Allen E., Rahman A., Isenberg D., Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years, 10.1093/rheumatology/kep062
  66. Steiman Amanda J., Gladman Dafna D., Ibañez Dominique, Urowitz Murray B., Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period, 10.1002/acr.21568
  67. STEIMAN A. J., GLADMAN D. D., IBANEZ D., UROWITZ M. B., Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome, 10.3899/jrheum.100007
  68. Tseng Chung-E, Buyon Jill P., Kim Mimi, Belmont H. Michael, Mackay Meggan, Diamond Betty, Marder Galina, Rosenthal Pamela, Haines Kathleen, Ilie Virginia, Abramson Steven B., The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial, 10.1002/art.22198
  69. Bootsma H., Spronk P., de Boer G., Limburg P., Kallenberg C., Derksen R., Wolters-Dicke J., Gmelig-Meyling F., Kater L., Hermans J., Prevention of relapses in systemic lupus erythematosus, 10.1016/s0140-6736(95)90114-0
  70. Birmingham DJ, Irshaid F., Nagaraja HN, Zou X., Tsao BP, Wu H., Yu CY, Hebert LA, Rovin BH, The complex nature of serum C3 and C4 as biomarkers of lupus renal flare, 10.1177/0961203310371154
  71. Bijl M., IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus, 10.1093/rheumatology/41.1.62
  72. Ng K. P., Manson J. J., Rahman A., Isenberg D. A., Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus, 10.1002/art.22356
  73. Ter Borg E. J., Horst G., Hummel E. J., Limburg P. C., Kallenberg C. G. M., Measurement of increases in anti-double-stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus, 10.1002/art.1780330505
  74. Swaak A J, Groenwold J, Bronsveld W, Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus., 10.1136/ard.45.5.359
  75. PETRI M., SINGH S., TESFASYONE H., MALIK A., Prevalence of Flare and Influence of Demographic and Serologic Factors on Flare Risk in Systemic Lupus Erythematosus: A Prospective Study, 10.3899/jrheum.090019
  76. Mirzayan M. J., Prognostic parameters for flare in systemic lupus erythematosus, 10.1093/rheumatology/39.12.1316
  77. Ho Audrey, Magder Laurence S., Barr Susan G., Petri Michelle, Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus, 10.1002/1529-0131(200110)44:10<2342::aid-art397>3.0.co;2-8
  78. Ho Audrey, Barr Susan G., Magder Laurence S., Petri Michelle, A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus, 10.1002/1529-0131(200110)44:10<2350::aid-art398>3.0.co;2-a
  79. Mok, J Rheumatol, 30, 1513 (2003)
  80. Laustrup H., Voss A., Green A., Junker P., SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study, 10.1177/0961203309351033
  81. Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, Grassi S, Alpigiani MG, Barbano G, Janz-Junior LL, Martini A, Ravelli A, Relationship between Damage Accrual, Disease Flares and Cumulative Drug Therapies in Juvenile-Onset Systemic Lupus Erythematosus, 10.1191/0961203306lu2316oa
  82. Swaak A J, Nossent J C, Bronsveld W, Van Rooyen A, Nieuwenhuys E J, Theuns L, Smeenk R J, Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively., 10.1136/ard.48.6.447
  83. Birnbaum J., Petri M., Thompson R., Izbudak I., Kerr D., Distinct subtypes of myelitis in systemic lupus erythematosus, 10.1002/art.24937
  84. Urowitz, J Rheumatol, 32, 1467 (2005)
  85. Mosca Marta, Bencivelli Walter, Neri Rossella, Pasquariello Antonio, Batini Valentina, Puccini Rodolfo, Tavoni Antonio, Bombardieri Stefano, Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis, 10.1046/j.1523-1755.2002.00280.x
  86. Moroni G., Quaglini S., Gallelli B., Banfi G., Messa P., Ponticelli C., The long-term outcome of 93 patients with proliferative lupus nephritis, 10.1093/ndt/gfm245
  87. Houssiau F. A., D'Cruz D., Sangle S., Remy P., Vasconcelos C., Petrovic R., Fiehn C., de Ramon Garrido E., Gilboe I.-M., Tektonidou M., Blockmans D., Ravelingien I., le Guern V., Depresseux G., Guillevin L., Cervera R., , Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial, 10.1136/ard.2010.131995
  88. Dooley Mary Anne, Jayne David, Ginzler Ellen M., Isenberg David, Olsen Nancy J., Wofsy David, Eitner Frank, Appel Gerald B., Contreras Gabriel, Lisk Laura, Solomons Neil, Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, 10.1056/nejmoa1014460
  89. Navarra Sandra V, Guzmán Renato M, Gallacher Alberto E, Hall Stephen, Levy Roger A, Jimenez Renato E, Li Edmund K-M, Thomas Mathew, Kim Ho-Youn, León Manuel G, Tanasescu Coman, Nasonov Eugeny, Lan Joung-Liang, Pineda Lilia, Zhong Z John, Freimuth William, Petri Michelle A, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(10)61354-2
  90. Merrill JT, Buyon JP, Furie RA, Latinis KM, Gordon C, Hsieh H-J, Brunetta P, Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER), 10.1177/0961203310395802
  91. Griffiths B., Emery P., Ryan V., Isenberg D., Akil M., Thompson R., Maddison P., Griffiths I. D., Lorenzi A., Miles S., Situnayake D., Teh L. S., Plant M., Hallengren C., Nived O., Sturfelt G., Chakravarty K., Tait T., Gordon C., The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE, 10.1093/rheumatology/kep396
  92. Furie Richard, Petri Michelle, Zamani Omid, Cervera Ricard, Wallace Daniel J., Tegzová Dana, Sanchez-Guerrero Jorge, Schwarting Andreas, Merrill Joan T., Chatham W. Winn, Stohl William, Ginzler Ellen M., Hough Douglas R., Zhong Z. John, Freimuth William, van Vollenhoven Ronald F., , A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, 10.1002/art.30613
  93. Strand, J Rheumatol, 26, 490 (1999)
  94. Morand (2013)
  95. Moroni Gabriella, Quaglini Silvana, Gravellone Luciana, Gallelli Beniamina, Leoni Antonio, Messa Piergiorgio, Sinico Renato Alberto, Membranous Nephropathy in Systemic Lupus Erythematosus: Long-Term Outcome and Prognostic Factors of 103 Patients, 10.1016/j.semarthrit.2011.08.002
  96. Mok Chi Chiu, Ying King Yee, Tang Sydney, Leung Chung Ying, Lee Ka Wing, Ng Woon Leung, Wong Raymond Woon Sing, Lau Chak Sing, Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis, 10.1002/art.20364
  97. Illei G. G., Takada K., Parkin D., Austin H. A., Crane M., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Pando J., Steinberg A. D., Gourley M. F., Klippel J. H., Balow J. E., Boumpas D. T., Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies, 10.1002/art.10142
  98. Nossent J., Kiss E., Rozman B., Pokorny G., Vlachoyiannopoulos P., Olesinska M., Marchesoni A., Mosca M., Påi S., Manger K., Schneider M., Nielsen H., van Vollenhoven R., Swaak T., Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus, 10.1177/0961203310366572
  99. Drenkard Cristina, Villa Antonio R., García-Padilla Carlos, Pérez-Vázquez María Esther, Alarcón-Segovia Donato, Remission of Systemic Lupus Erythematosus : , 10.1097/00005792-199603000-00005
  100. Tisseverasinghe Annaliese, Lim Sooyeol, Greenwood Celia, Urowitz Murray, Gladman Dafna, Fortin Paul R., Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus, 10.1002/art.21929
  101. Reich Heather N., Gladman Dafna D., Urowitz Murray B., Bargman Joanne M., Hladunewich Michelle A., Lou Wendy, Fan Steve C.P., Su Jiandong, Herzenberg Andrew M., Cattran Daniel C., Wither Joan, Landolt-Marticorena Carol, Scholey James W., Fortin Paul R., Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus, 10.1038/ki.2010.525
  102. Arends Suzanne, Grootscholten Cecile, Derksen Ronald HWM, Berger Stefan P, de Sévaux Ruud GL, Voskuyl Alexandre E, Bijl Marc, Berden Jo HM, Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis, 10.1136/annrheumdis-2011-200384
  103. Manger K, Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus, 10.1136/ard.61.12.1065
  104. Andrade R M, Alarcon G S, Gonzalez L A, Fernandez M, Apte M, Vila L M, McGwin G, Reveille J D, , Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV), 10.1136/ard.2007.077594
  105. Stoll T., Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study, 10.1093/rheumatology/keh238
  106. Bertoli A. M., Vila L. M., Apte M., Fessler B. J., Bastian H. M., Reveille J. D., Alarcon G. S., , Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual, 10.1093/rheumatology/kem153
  107. Lopez R., Davidson J. E., Beeby M. D., Egger P. J., Isenberg D. A., Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort, 10.1093/rheumatology/ker368
  108. Andrade Rosa M., Alarcón Graciela S., Fernández Mónica, Apte Mandar, Vilá Luis M., Reveille John D., , Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort, 10.1002/art.22375
  109. Ibanez, J Rheumatol, 30, 1977 (2003)
  110. Petri Michelle, Purvey Sneha, Fang Hong, Magder Laurence S., Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort, 10.1002/art.34672
  111. Gladman Dafna, Ginzler Ellen, Goldsmith Charles, Fortin Paul, Liang Matthew, Sanchez-Guerrero Jorge, Urowitz Murray, Bacon Paul, Bombardieri Stefano, Hanly John, Jones John, Hay Elaine, Symmons Deborah, Isenberg David, Kalunion Kenneth, Maddison Peter, Nived Ola, Sturfelt Gunnar, Petri Michelle, Richter Martin, Snaith Michael, Zoma Asad, The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus, 10.1002/art.1780390303
  112. Mosca M., Tani C., Aringer M., Bombardieri S., Boumpas D., Brey R., Cervera R., Doria A., Jayne D., Khamashta M. A., Kuhn A., Gordon C., Petri M., Rekvig O. P., Schneider M., Sherer Y., Shoenfeld Y., Smolen J. S., Talarico R., Tincani A., van Vollenhoven R. F., Ward M. M., Werth V. P., Carmona L., European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies, 10.1136/ard.2009.117200
  113. Group OLoEW. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. In: Group OLoEW, ed., 2011.
  114. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project, 10.1136/qhc.12.1.18
  115. Nived, J Rheumatol, 29, 1398 (2002)
  116. Smolen Josef S, Braun Jürgen, Dougados Maxime, Emery Paul, FitzGerald Oliver, Helliwell Philip, Kavanaugh Arthur, Kvien Tore K, Landewé Robert, Luger Thomas, Mease Philip, Olivieri Ignazio, Reveille John, Ritchlin Christopher, Rudwaleit Martin, Schoels Monika, Sieper Joachim, Wit Martinus de, Baraliakos Xenofon, Betteridge Neil, Burgos-Vargas Ruben, Collantes-Estevez Eduardo, Deodhar Atul, Elewaut Dirk, Gossec Laure, Jongkees Merryn, Maccarone Mara, Redlich Kurt, van den Bosch Filip, Wei James Cheng-Chung, Winthrop Kevin, van der Heijde Désirée, Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force, 10.1136/annrheumdis-2013-203419
  117. Smolen J. S., Aletaha D., Bijlsma J. W. J., Breedveld F. C., Boumpas D., Burmester G., Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J. J., Haraoui B., Kalden J., Keystone E. C., Kvien T. K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D., , Treating rheumatoid arthritis to target: recommendations of an international task force, 10.1136/ard.2009.123919
  118. Möttönen Timo, Hannonen Pekka, Leirisalo-Repo Marjatta, Nissilä Martti, Kautiainen Hannu, Korpela Markku, Laasonen Leena, Julkunen Heikki, Luukkainen Reijo, Vuori Kaisa, Paimela Leena, Blåfield Harri, Hakala Markku, Ilva Kirsti, Yli-Kerttula Urpo, Puolakka Kari, Järvinen Pentti, Hakola Mikko, Piirainen Heikki, Ahonen Jari, Pälvimäki Ilppo, Forsberg Sinikka, Koota Kalevi, Friman Claes, Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial, 10.1016/s0140-6736(98)08513-4
  119. Verstappen S M M, Jacobs J W G, van der Veen M J, Heurkens A H M, Schenk Y, ter Borg E J, Blaauw A A M, Bijlsma J W J, , Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial), 10.1136/ard.2007.071092
  120. Grigor Catriona, Capell Hilary, Stirling Anne, McMahon Alex D, Lock Peter, Vallance Ramsay, Porter Duncan, Kincaid Wilma, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, 10.1016/s0140-6736(04)16676-2
  121. Eastman Richard C, Keen Harry, The impact of cardiovascular disease on people with diabetes: the potential for prevention, 10.1016/s0140-6736(97)90026-x
  122. SWALES P, Pharmacological treatment of hypertension, 10.1016/s0140-6736(94)91405-2
Bibliographic reference van Vollenhoven, Ronald F ; Mosca, Marta ; Bertsias, George ; Isenberg, David ; Kuhn, Annegret ; et. al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.. In: Annals of the rheumatic diseases, Vol. 73, no.6, p. 958-67 (2014)
Permanent URL http://hdl.handle.net/2078.1/146033